234 related articles for article (PubMed ID: 19901153)
1. The case for dual Renin-Angiotensin system inhibition.
Hirsch S
Arch Intern Med; 2009 Nov; 169(20):1931; author reply 1931. PubMed ID: 19901153
[No Abstract] [Full Text] [Related]
2. [Dual blockade of the renin-angiotensin system].
Andersen NH; Mogensen CE
Ugeskr Laeger; 2004 Oct; 166(43):3799-803. PubMed ID: 15544108
[No Abstract] [Full Text] [Related]
3. Renin-angiotensin system inhibitors in proteinuric chronic kidney disease.
Hirsch S
Compr Ther; 2009; 35(2):91-5. PubMed ID: 19618757
[TBL] [Abstract][Full Text] [Related]
4. Is there added value to adding ARB to ACE inhibitors in the management of CKD?
Cohen DL; Townsend RR
J Am Soc Nephrol; 2009 Aug; 20(8):1666-8. PubMed ID: 18776118
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the renin-angiotensin system in cardiovascular protection: Is it important to watch your C'ARB' intake?
Strauss MH; Verma S
Can J Cardiol; 2005 May; 21(7):577-80. PubMed ID: 15940355
[No Abstract] [Full Text] [Related]
6. Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers.
Berl T
Nephrol Dial Transplant; 2008 Aug; 23(8):2443-7. PubMed ID: 18467376
[No Abstract] [Full Text] [Related]
7. Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.
Papademetriou V
Am Heart J; 2009 Jun; 157(6 Suppl):S24-30. PubMed ID: 19450721
[TBL] [Abstract][Full Text] [Related]
8. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.
Bakris GL; Weir MR
Postgrad Med; 2008 Apr; 120(1):33-42. PubMed ID: 18467807
[TBL] [Abstract][Full Text] [Related]
9. Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction.
Gradman AH; Papademetriou V
Am Heart J; 2009 Jun; 157(6 Suppl):S17-23. PubMed ID: 19450720
[TBL] [Abstract][Full Text] [Related]
10. Dual renin-angiotensin system blockade: in patients with single functioning kidney and proteinuria.
Robles NR; Ruiz Jiménez B; Hernández Gallego R; Ruiz-Calero R; Sánchez Casado E; Cubero JJ
Eur J Intern Med; 2009 Mar; 20(2):186-9. PubMed ID: 19327610
[TBL] [Abstract][Full Text] [Related]
11. Dual renin-angiotensin system blockade: on the target.
Robles NR
Int J Clin Pract; 2008 Aug; 62(8):1134-6. PubMed ID: 18705817
[No Abstract] [Full Text] [Related]
12. The hazards of dual renin-angiotensin blockade in chronic kidney disease.
Ku E; Park J; Vidhun J; Campese V
Arch Intern Med; 2009 Jun; 169(11):1015-8. PubMed ID: 19506167
[No Abstract] [Full Text] [Related]
13. The renin-angiotensin-aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease.
Brugts JJ; den Uil CA; Danser AH; Boersma E
Cardiology; 2009; 112(4):303-12. PubMed ID: 18832826
[TBL] [Abstract][Full Text] [Related]
14. [The early diagnosis of kidney failure in diabetic patients and the new developments in its treatment].
Eliseev OM
Ter Arkh; 1995; 67(4):66-9. PubMed ID: 7784984
[No Abstract] [Full Text] [Related]
15. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease.
Ripley E
Am Heart J; 2009 Jun; 157(6 Suppl):S7-S16. PubMed ID: 19450722
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises.
Palmer BF
Nephrol Dial Transplant; 2003 Oct; 18(10):1973-5. PubMed ID: 13679467
[No Abstract] [Full Text] [Related]
17. Angiotensin and its inhibition: a nephrologist point of view.
Kalra V; Agarwal SK; Wani M
J Assoc Physicians India; 2002 Oct; 50():1270-80. PubMed ID: 12568213
[No Abstract] [Full Text] [Related]
18. Treating diabetic nephropathy: unfinished success is not failure.
Lewis J
Clin J Am Soc Nephrol; 2007 May; 2(3):407-9. PubMed ID: 17699442
[No Abstract] [Full Text] [Related]
19. Aliskiren combined with losartan in diabetes and nephropathy.
Anderson S; Komers R
N Engl J Med; 2008 Sep; 359(10):1069; author reply 1069-70. PubMed ID: 18777613
[No Abstract] [Full Text] [Related]
20. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials.
Boos CJ; Lip GY
J Hum Hypertens; 2005 Nov; 19(11):855-9. PubMed ID: 16094406
[No Abstract] [Full Text] [Related]
[Next] [New Search]
